Skip to content
Bilcare logo

Bilcare

BI NSE
₹77.36 −1.81 (−2.29%)
P/E
12.42
View as Markdown
MCP
Close 4 Nov 2026 ₹77.36 −23.64 −23.4% 1Y
Start ₹101.00

Key Fundamentals

MicrocapHealthcare ServicesHealthcare

Price-based figures as of · EPS basis: Consolidated · TTM

ROCE
7.06%
Debt to Equity
3.15
EPS (TTM)
₹6.23
Book Value
₹83.55
Market Cap
—
P/E (TTM)
12.42
P/B
0.93
ROE
1.39%
Dividend Yield
0.00%
EBITDA
₹74.40 Cr
52W High
₹113.00
52W Low
₹50.00
Day Range
₹75.71 – ₹79.00
Volume
18,674

Peer Comparison

Healthcare › Healthcare Technology › Healthcare Research, Analytics & Technology

Bilcare peer comparison
Syngene International
₹417.5076.05₹16,536 Cr3.470.31%7.78%9.99%₹3,600 Cr₹221 Cr
Indegene
₹617.1037.04₹14,947 Cr4.430.37%14.40%18.80%₹3,813 Cr₹401 Cr
Suven Life Sciences
₹276.10—₹7,549 Cr11.390.00%−81.50%−79.50%₹9 Cr−₹353 Cr
Vimta Labs
₹497.8527.89₹2,195 Cr4.530.41%18.90%25.20%₹419 Cr₹80 Cr
Fabtech Technologies
₹132.309.94₹589 Cr1.340.46%12.50%13.60%₹418 Cr₹49 Cr
Bilcare (this company)
₹77.3612.42₹178 Cr0.930.00%1.39%7.06%₹773 Cr−₹6 Cr
Take
₹11.4213.13₹161 Cr5.440.00%16.50%18.50%₹85 Cr₹13 Cr
Median 7 companies₹276.1020.51₹2,195 Cr4.430.31%12.50%13.60%₹419 Cr₹49 Cr

Comparable companies in the same industry. Market cap, P/E and P/B use the latest price; other metrics are as reported in filings. A dash means the figure is not published for that company. 1 company is not shown because they are not listed on an exchange we cover.

Tapetide Score

Data-driven rating, 0–100, as of . How it works →

Overall score

50 Average

Data confidence 98/100

surveillance:ESM1

Category scores

Quality
50
Average
Returns, margins, earnings quality 22% weight
Valuation
76
Strong
Cheap vs sector & own history 24% weight
Growth
36
Poor
Sales & profit trajectory 9% weight
Financial Health
21
Poor
Solvency, leverage, coverage 9% weight
Momentum
71
Strong
Trend strength, vol-adjusted 12% weight
Ownership
50
Average
FII/DII/promoter flows 24% weight

The Tapetide Score is data analysis, not investment advice. Tapetide is not a SEBI-registered research analyst or investment adviser.

Key Insights

Strengths

1
  • Stock is trading at 1.13 times its book value

Weaknesses

5
  • Company has low interest coverage ratio.
  • The company has delivered a poor sales growth of 3.33% over past five years.
  • Promoter holding is low: 30.0%
  • Company has a low return on equity of -2.83% over last 3 years.
  • Contingent liabilities of Rs.725 Cr.

Technical Indicators

Technical signals: verdict and indicator counts
GroupSignalBearishNeutralBullish
OverallStrong Bearish1063
OscillatorsBearish261
Moving AveragesStrong Bearish802

Key readings

RSI (14)
34.23
Neutral
MACD (12,26,9)
−4.33
Bearish
SMA (50)
92.39
Bearish
SMA (200)
70.44
Bullish

As of

Growth Rate

From the financial statements below. 10Y, 5Y, 3Y: compound annual growth to Mar 2026; 1Y: fiscal year to Mar 2026 against Mar 2025; TTM: four quarters to Jun 2026 against Jun 2025.

Revenue

Revenue growth by window
10Y−11.89%
5Y+3.33%
3Y−9.25%
1Y−6.85%
TTM−0.90%

Net profit

Net profit growth by window
10YLoss narrowed by ₹65 Cr
5YLoss widened by ₹6 Cr
3YTurned to loss
1YLoss narrowed by ₹11 Cr
TTMLoss narrowed by ₹38 Cr

Operating cash flow

Operating cash flow growth by window
10Y−3.19%
5Y+12.20%
3YTurned positive
1Y+48.84%
TTM—

TTM: Reported once a year, so there is no trailing-twelve-month figure.

Operating margin· change in pp

Operating margin growth by window
10Y−1.82 pp
5Y−2.06 pp
3Y+0.33 pp
1Y+0.29 pp
TTM+4.19 pp

Revenue by year

Revenue by year, ₹ crore
Mar 2017₹2,633 Cr
Mar 2018₹2,778 Cr
Mar 2019₹2,997 Cr
Mar 2020₹1,827 Cr
Mar 2021₹623 Cr
Mar 2022₹845 Cr
Mar 2023₹982 Cr
Mar 2024₹747 Cr
Mar 2025₹788 Cr
Mar 2026₹734 Cr

Net profit by year

Net profit by year, ₹ crore
Mar 2017−₹80.00 Cr
Mar 2018−₹199 Cr
Mar 2019−₹453 Cr
Mar 2020−₹99.00 Cr
Mar 2021−₹11.00 Cr
Mar 2022−₹4.00 Cr
Mar 2023₹50.00 Cr
Mar 2024−₹59.00 Cr
Mar 2025−₹28.00 Cr
Mar 2026−₹17.00 Cr

Quarterly Results

₹ Cr
526853 quarterly results, ₹ crore
Particulars Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
182
190
175
200
194
202
198
194
186
178
181
188
226
Expenses
169
173
158
208
175
194
187
186
175
175
168
171
189
Operating Profit
13
17
17
−8
19
8
11
8
11
3
13
17
37
OPM %
7%
9%
10%
−4.1%
10%
3.8%
5%
4%
6%
1.9%
7%
9%
16%
Other Income
3
1
4
9
4
−6
−6
21
6
4
3
12
0
Interest
19
20
21
23
21
24
19
19
19
19
17
18
18
Depreciation
10
10
11
13
12
11
12
5
12
12
5
5
4
PBT
−13
−13
−10
−35
−10
−33
−27
6
−13
−24
−6
7
15
Tax %
−1%
−5%
34%
−44%
55%
−10%
−40%
−119%
−25%
−1%
3%
−13%
−1%
Net Profit
−13
−12
−14
−20
−15
−30
−16
12
−10
−23
−6
8
15
EPS (₹)
−3.36
−3.22
−2.91
−4.63
−2.71
−6.81
−3.04
7.47
−1.61
−5.25
0.41
5.68
5.39

Profit & Loss

₹ Cr
526853 profit and loss, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
2,692
2,603
2,633
2,778
2,997
1,827
623
845
982
747
788
734
773
Expenses
2,506
2,396
2,443
2,617
2,827
1,782
572
784
925
708
742
689
703
Operating Profit
186
207
190
161
170
45
51
60
57
39
46
45
70
OPM %
7%
8%
7%
6%
6%
2.5%
8%
7%
6%
5%
6%
6%
9%
Other Income
9
−87
107
297
59
254
45
44
237
16
12
26
20
Interest
236
151
176
249
283
174
76
69
60
82
83
72
72
Depreciation
191
164
177
416
378
239
46
39
38
45
18
20
26
PBT
−232
−194
−56
−207
−433
−114
−25
−4
196
−72
−43
−21
−7
Tax %
−7%
−58%
42%
−4%
5%
−13%
−55%
3%
74%
−18%
−35%
−19%
—
Net Profit
−216
−82
−80
−199
−453
−99
−11
−4
50
−59
−28
−17
−6
EPS (₹)
−91.76
−36.04
−35.91
−85.43
−193
−43.97
−8.95
−5.35
6.39
−14.12
−0.33
0.73
6.23
Div. Payout %
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
0%
—

Balance Sheet

₹ Cr
526853 balance sheet, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
24
24
24
24
24
24
24
24
24
24
24
24
Reserves
1,073
689
590
376
−93
85
63
52
507
474
191
173
Borrowings
2,311
2,122
2,014
2,089
2,270
707
677
690
639
756
689
620
Other Liabilities
933
786
830
913
888
297
300
362
424
314
21
26
Total Liabilities
4,340
3,620
3,457
3,402
3,087
1,112
1,064
1,127
1,593
1,568
924
843
Fixed Assets
1,926
2,432
2,403
2,180
2,005
534
494
465
1,045
1,038
456
432
CWIP
218
161
149
170
79
0
0
1
1
1
4
10
Investments
0
1
0
1
0
0
0
0
2
8
11
14
Other Assets
2,196
1,026
904
1,051
1,003
577
570
661
545
521
453
387
Total Assets
4,340
3,620
3,457
3,402
3,087
1,112
1,064
1,127
1,593
1,568
924
843

Cash Flow

₹ Cr
526853 cash flow, annual, ₹ crore
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
−315
177
300
98
206
256
72
41
−7
62
86
128
Investing
247
−358
−129
−203
−104
1,309
2
−4
36
−106
81
−5
Financing
119
149
−155
91
−103
−1,600
−83
−55
−19
36
−171
−132
Net Cash Flow
50
−32
16
−13
−1
−35
−9
−18
10
−7
−3
−10
Free Cash Flow
−74
−12
165
−115
91
1,569
69
37
11
−34
142
120
CFO/OP
−170
85
173
75
148
828
141
78
−6
162
192
283

Ratios

526853 financial ratios, annual
Particulars Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
125
35
29
38
38
22
90
95
70
73
55
54
Inventory Days
105
108
84
90
82
28
90
83
42
77
80
86
Days Payable
93
86
81
102
71
35
93
102
77
70
57
70
Cash Conversion Cycle
137
57
32
25
49
15
88
76
34
80
78
69
Working Capital Days
125
5
−11
−150
−156
−2
−19
−10
−10
12
−5
28
ROCE %
1%
2%
2%
−8%
−6%
−9%
3%
3%
3%
1%
4%
7%

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Bilcare insights

59 extracted metrics across FY15–FY27.

Shareholding Pattern

As of Sep 2026

  • Public 45.33%
  • Promoters 30.01%
  • Others 24.61%
  • FIIs 0.04%

1.39% of promoter holding pledged as of 14 Oct 2026

Change vs previous quarter

Documents

Frequently Asked Questions about Bilcare

What does Bilcare Ltd do?
Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).
Where is Bilcare Ltd (BI) listed?
Bilcare Ltd trades as BI on the NSE and under code 526853 on the BSE.
Which sector does Bilcare Ltd belong to?
Bilcare Ltd is classified under the Healthcare sector, in the Healthcare Technology industry.
What is the PE ratio of Bilcare Ltd?
Bilcare Ltd trades at a PE ratio of 12.42 as of 4 Nov 2026, on earnings per share of ₹6.23, against a book value of ₹83.55 per share.
What is the 52-week high and low of Bilcare Ltd?
Over the last 52 weeks Bilcare Ltd has traded between ₹50 and ₹113 as of 4 Nov 2026.
What is the Return on Equity (ROE) of Bilcare Ltd?
Bilcare Ltd reported a return on equity of 1.39%. Its debt-to-equity ratio is 3.15.

Company Information

Incorporated in 1987, Bilcare Ltd. is engaged in the business of Pharmaceutical Packaging, Global Clinical Services, R&D services and Anti Counterfeit Technology (nCid).

Website bilcare-group.com
Listed 20 Apr 2026
Face Value ₹10

For AI agents and developers

Reading this as an AI agent, LLM or automated pipeline? Every page on Tapetide is also published as clean Markdown — no navigation, no scripts, just the data. Fetch https://tapetide.com/stocks/526853.md for Bilcare Ltd: dated key facts, then this page's sections in order: latest price, key fundamentals, peer comparison, the Tapetide Score, technical indicators, analyst ratings, growth rates, analyst forecasts, the AI analysis and news digest (labelled as AI-generated), financial statements, shareholding pattern, documents and the FAQ.

Append .md to any Tapetide URL for the same treatment. A full index of what we publish is at /llms.txt and /llms-full.txt. For live, structured queries instead of documents, use our Indian stock market MCP server.

Explore More

More Hospital & Healthcare Services stocks → FII DII DataStock ScreenerNifty 50 HeatmapF&O Ban ListFII and DII flows, month by monthHow Tapetide Scores changed, month by monthStocks mutual funds are buying, month by month